Patient's characteristics
Patient no. . | Sex . | Age, y . | KP, % . | Dose level, mg . | Wks on/off treatment . | FLT3 mutation . | Pretherapy absolute blast count, × 109/L . | Previous treatment . | Treatment duration, no. cycles . | Best response . | Reason off-study . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 54 | 60 | 50 | 4/2 | FLT3-WT | 3.64 | No | < 1 | NE | PD |
| 2 | F | 72 | 80 | 50 | 4/2 | FLT3-WT | 0.13 | No | 2 | MR | PD |
| 3 | M | 80 | 70 | 50 | 4/2 | FLT3-D835 | 4.30 | No | 1 | MorphR | PD |
| 4 | M | 73 | 80 | 50 | 4/2 | FLT3-WT | 0.46 | No | 1 | PD | PD |
| 5 | M | 72 | 70 | 50 | 4/2 | FLT3-WT | 8.64 | Yes | < 1 | PD | PD |
| 6 | F | 76 | 100 | 50 | 4/2 | NA | 0.07 | No | 1 | PD | PD |
| 7 | F | 73 | 80 | 50 | 4/2 | FLT3-ITD | 0.90 | No | 2 | PR | AE (1) |
| 8 | F | 64 | 70 | 50 | 4/2 | FLT3-D835 | 3.35 | Yes | 2 | PR | PD |
| 9 | M | 60 | 70 | 75 | 4/2 | FLT3-WT | 0.39 | Yes | 1 | PR | AE (2) |
| 10 | F | 77 | 90 | 75 | 4/2 | FLT3-WT | 0.00 | Yes | < 1 | NE | DLT |
| 11 | F | 59 | 90 | 50 | 4/1 | FLT3-WT | 3.83 | Yes | < 1 | SD | AE (3) |
| 12 | F | 71 | 90 | 50 | 4/1 | FLT3-WT | 0.00 | No | 1 | SD | AE (4) |
| 13 | F | 68 | 100 | 50 | 4/1 | FLT3-ITD | 98.75 | Yes | 3 | PR | AE (5) |
| 15 | F | 55 | 80 | 50 | 4/1 | FLT3-WT | 0.06 | Yes | 3 | PR | PD |
| 16 | M | 72 | 80 | 50 | 4/1 | FLT3-WT | 0.00 | Yes | 1 | SD | PD |
Patient no. . | Sex . | Age, y . | KP, % . | Dose level, mg . | Wks on/off treatment . | FLT3 mutation . | Pretherapy absolute blast count, × 109/L . | Previous treatment . | Treatment duration, no. cycles . | Best response . | Reason off-study . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 54 | 60 | 50 | 4/2 | FLT3-WT | 3.64 | No | < 1 | NE | PD |
| 2 | F | 72 | 80 | 50 | 4/2 | FLT3-WT | 0.13 | No | 2 | MR | PD |
| 3 | M | 80 | 70 | 50 | 4/2 | FLT3-D835 | 4.30 | No | 1 | MorphR | PD |
| 4 | M | 73 | 80 | 50 | 4/2 | FLT3-WT | 0.46 | No | 1 | PD | PD |
| 5 | M | 72 | 70 | 50 | 4/2 | FLT3-WT | 8.64 | Yes | < 1 | PD | PD |
| 6 | F | 76 | 100 | 50 | 4/2 | NA | 0.07 | No | 1 | PD | PD |
| 7 | F | 73 | 80 | 50 | 4/2 | FLT3-ITD | 0.90 | No | 2 | PR | AE (1) |
| 8 | F | 64 | 70 | 50 | 4/2 | FLT3-D835 | 3.35 | Yes | 2 | PR | PD |
| 9 | M | 60 | 70 | 75 | 4/2 | FLT3-WT | 0.39 | Yes | 1 | PR | AE (2) |
| 10 | F | 77 | 90 | 75 | 4/2 | FLT3-WT | 0.00 | Yes | < 1 | NE | DLT |
| 11 | F | 59 | 90 | 50 | 4/1 | FLT3-WT | 3.83 | Yes | < 1 | SD | AE (3) |
| 12 | F | 71 | 90 | 50 | 4/1 | FLT3-WT | 0.00 | No | 1 | SD | AE (4) |
| 13 | F | 68 | 100 | 50 | 4/1 | FLT3-ITD | 98.75 | Yes | 3 | PR | AE (5) |
| 15 | F | 55 | 80 | 50 | 4/1 | FLT3-WT | 0.06 | Yes | 3 | PR | PD |
| 16 | M | 72 | 80 | 50 | 4/1 | FLT3-WT | 0.00 | Yes | 1 | SD | PD |
AE 1 used to indicate acute myocardial infarction; AE 2, cardiac failure; DLT, fatigue grade 4; AE 3, sepsis; AE 4, pneumonia; AE 5, cerebral bleeding. KP indicates Karnofsky performance status; NE, not evaluable; AE, adverse event.